Efficacy of a novel oral formulation of sarolaner (Simparica™) against five common tick species infesting dogs in the United States

The efficacy of a single oral treatment with sarolaner (Simparica (TM), Zoetis), a novel isoxazoline compound, was evaluated against five tick species known to infest dogs in the United States. A total of 10 laboratory studies, two against each species, were conducted using adult purpose-bred mongrels or Beagle dogs. In each study, 16 dogs were randomly allocated to one of two treatment groups based on pre-treatment host suitability tick counts. Dogs were infested with approximately 50 unfed adult Amblyomma americanum, Amblyomma maculatum, Dermacentor variabilis, Ixodes scapularis or Rhipicephalus sanguineus ticks on Days -2, 5, 12, 19, 26 and 33. On Day 0, dogs were treated with a placebo or a sarolaner tablet providing a minimum dose of 2 mg/kg. Tick counts were conducted 48 h after treatment and after each subsequent weekly re-infestation. There were no treatment-related adverse reactions during any of the studies. Dogs in the placebo treated group maintained tick infestations throughout the studies. Geometric mean live tick counts were significantly lower (P <= 0.0001) in the sarolaner-treated group compared to the tick counts in the placebo group at all timepoints. Treatment with sarolaner resulted in >= 99.6% efficacy against existing infestations of all five tick species within 48 h. The efficacy against weekly post-treatment re-infestations of all tick species was >= 96.9% for at least 35 days after treatment. Thus, a single dose of sarolaner administered orally at the minimum dosage of 2 mg/kg, resulted in excellent efficacy within 48 h against existing tick infestations, and against weekly re-infestations for 35 days after treatment. These studies confirmed that administration of the minimum dose of sarolaner will provide rapid treatment of existing infestations and give at least one month of control against re infestation by the common tick species affecting dogs in the US. (C) 2016 The Authors. Published by Elsevier B.V.